A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

Launched by AUGUSTA UNIVERSITY · Apr 1, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating whether a shorter, seven-day treatment with antifungal medication is as effective as the standard 14-day treatment for patients with uncomplicated candidemia, which is a type of infection caused by yeast in the bloodstream. The goal is to see if the shorter treatment can help patients recover just as well without causing more side effects or increasing the risk of death.

To participate in this trial, you need to be at least 18 years old and have a confirmed case of uncomplicated candidemia, meaning there are no signs of a more serious infection. You should not have received more than five days of antifungal treatment before joining the study. If you decide to participate, you will be randomly assigned to receive either the seven-day or the 14-day treatment. The trial is not currently recruiting participants, so it’s important to keep an eye out for updates if you or someone you know might be interested in joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients ≥ 18 years of age
• • 2. Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7.
• • 3. Received \< 5 days of prior antifungal therapy
• • 4. Informed Consent for randomization
• • 5. Patients that did not consent to randomization have consented to be used as a natural history (controls) and will allow collection of available data from the medical record.
• Exclusion Criteria:
• • 1. Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters).
• • 2. Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood)
• • 3. Abnormal LFTs \> 10-fold
• • 4. Greater than 5 days of prior antifungal therapy
• • 5. Endovascular devices that cannot be removed.
• • 6. Immunocompromised patients (AIDS/HIV; solid organ transplant, bone marrow transplant patients, oncology patients receiving chemotherapy, neutropenic patients (ANC of \< 1,500 cells/L
• • 7. Neutropenic at time of consent (what does this mean)
• • 8. Break-through candidemia (people with prior candidemia who relapsed) after treatment with antifungal therapy)
• • 9. Unable to provide informed consent from either the patient or legally authorized authority (LAR)
• • 10. Expected mortality within 96 hours